公司概述
Niagen Bioscience, Inc. operates as a specialized bioscience entity focused on the development and commercialization of healthy aging products, serving consumers and ingredient markets through its distinct Consumer products, Ingredients, and Pharmaceutical Segments. The company functions within the broader Healthcare sector, specifically targeting the high-growth Biotechnology industry, which implies a strategic focus on innovation-driven solutions and proprietary intellectual property. With a total market capitalization of $358.76 million, the firm demonstrates a mid-to-large cap status for a biotechnology enterprise, supported by an annual revenue of $129.42 million and an operational workforce of 117 employees. These valuation and revenue figures indicate that the company has achieved significant market penetration and commercial scale, positioning it as an established player capable of sustaining R&D investments while generating substantial top-line growth in a competitive therapeutic landscape.
财务健康
The company reported trailing twelve-month revenue of $129.42 million, accompanied by a net income of $17.38 million and an EBITDA of $15.08 million, highlighting a substantial disparity between gross earnings and bottom-line profit that reveals a robust cost structure with significant operating expenses impacting the final net margin. Despite a profit margin of 13.4%, the operating margin sits at a more conservative 6.2%, suggesting that while the core business is profitable, non-operating items or specific accounting adjustments play a notable role in the final earnings calculation. The firm maintains a free cash flow of $4.88 million, which provides essential financial flexibility to fund ongoing research and development initiatives without immediate reliance on external equity financing. On the balance sheet, Niagen holds $64.64 million in cash against $2.82 million in debt, resulting in a debt-to-equity ratio of 3.68, which indicates a leveraged capital structure where equity capital is significantly larger than debt obligations. The current ratio stands at 4.86, signaling exceptionally strong short-term liquidity and the ability to comfortably meet obligations due within the next year using current assets. Furthermore, the return on equity of 28.3% and return on assets of 10.2% demonstrate that management is effectively utilizing shareholder capital and company assets to generate superior returns relative to industry peers.
估值评估
The stock currently trades with a trailing twelve-month P/E ratio of 22.40 and a forward P/E of 14.00, implying that the market expects earnings growth that would justify a significant multiple compression or a substantial increase in profitability to align future valuations with current price levels. The price-to-book ratio is recorded at 4.68, indicating that the market assigns a substantial premium to the company's intangible assets, such as its proprietary aging technologies, over its tangible book value. Alternative valuation metrics further illustrate this positioning, with a price-to-sales ratio of 2.77 and an EV/EBITDA of 19.74, suggesting that investors are willing to pay a premium for revenue and cash-flow generation relative to the company's historical earnings power. In terms of price volatility, the 52-week high is $14.69 and the low is $4.16, placing the current trading price within a wide historical range that reflects both significant past corrections and recent recoveries. The stock exhibits a beta of 2.23, meaning its price movements are expected to be more than twice as volatile as the broader market, introducing higher systematic risk for portfolio holders seeking stability.
Growth & Income
Recent financial performance shows a revenue growth rate of 16.2% year-over-year contrasted with an earnings growth rate of -41.6%, indicating that top-line expansion is outpacing bottom-line profitability, a common dynamic in biotechnology firms facing elevated R&D or restructuring costs. As the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all generated earnings are retained within the organization to fund capital expenditures, strategic acquisitions, or further research into healthy aging formulations. This reinvestment strategy prioritizes long-term market share expansion and technological advancement over immediate income distribution to shareholders, a typical approach for growth-stage biotech entities. Overall, the company presents a growth-oriented profile characterized by strong top-line momentum and a leveraged balance sheet that supports aggressive expansion while foregoing dividend income.